Literature DB >> 27148418

Lung cancer burden has increased during the last 40 years in Hebei Province, China.

Yutong He1, Daojuan Li1, Guohui Song2, Yongwei Li3, Di Liang1, Jing Jin1, Denggui Wen1, Baoen Shan1.   

Abstract

BACKGROUND: In 2011, Hebei Province, located in North China with a population of 71 794 239, accounted for approximately 6% of the national population. It is well known as a heavily air polluted area. This study reports the lung cancer burden and mortality trend in Hebei Province from 1973 to 2011.
METHODS: Eight cancer registries in Hebei Province submitted data to the Hebei Provincial Cancer Registry Center. Pooled data were stratified by area (urban/rural), gender, and age group. The proportions, cumulative incidence/mortality rates, and median age at death of lung cancer were calculated. Lung cancer mortality data of 1973-1975, 1990-1992, and 2004-2005 were extracted from national death surveys. Data of lung cancer from Cixian and Shexian were obtained from population-based cancer registries in each county.
RESULTS: The estimated numbers of newly diagnosed lung cancer cases and deaths in 2011 in Hebei Province were 32 623 and 27 612, respectively. The crude incidence rate of lung cancer was 45.44/100 000. The age-standardized incidence rate by world standard population was 39.01/100 000, ranking second among all cancers. The lung cancer mortality rate was 38.46/100 000, ranking first among all cancer deaths, with a significantly increasing trend in Hebei Province from 1973-1975 to 2010-2011, with an increased rate of 189.15%.
CONCLUSION: Hebei Province suffers a heavy disease burden of lung cancer and an obvious increasing trend has been observed over the past 40 years. Preventive and control strategies should be encouraged.

Entities:  

Keywords:  Cancer registry; heavy air pollution area; incidence rate; lung cancer; mortality rate

Year:  2016        PMID: 27148418      PMCID: PMC4846621          DOI: 10.1111/1759-7714.12331

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


Introduction

Lung cancer is a major worldwide public health problem. Globocan 2012 reported an estimated 1.8 million new lung cancer cases in 2012 (12.9% of the total) and 1.59 million deaths, accounting for almost one in five cancer deaths (19.4% of the total) in the world. In most Western countries, lung cancer incidence and mortality rates have been decreasing; in the United States (US), lung cancer incidence significantly decreased among men, although it remained stable among women during 2004–2009.1 In contrast, lung cancer incidence and mortality rates are still increasing in China.1, 2, 3 Many estimates suggest that the lung cancer burden resulting from air pollution is substantial. The International Agency for Research on Cancer (IARC) recently classified air pollution and PM as carcinogenic to humans.4 Particulate matter is the main contributor of ambient air pollution, and is carcinogenic. Exposure to ambient fine particles (PM2.5) was recently estimated to have contributed to 3.2 million premature deaths worldwide in 2010 and 223 000 deaths from lung cancer.5 Air pollution presents an increasingly serious problem in China, particularly in Hebei Province. Thus, in this paper, we analyze lung cancer incidence and mortality rates over a long period of time. There are eight population‐based cancer registries in Hebei Province, including 4 573 293 residents, accounting for 6.37% of the whole population in 2011. Hebei Province took part in three national death surveys, conducted during 1973–1975, 1990–1992, and 2004–2005. Both the Cixian and Shexian cancer registries are population‐based. This study reports the lung cancer burden in 2011 and provides a summary overview of trends in lung cancer mortality in Hebei Province from 1973 to 2011. It also shows lung cancer incidence and mortality trends in Cixian (1988–2011) and Shexian (2000–2011) by analyzing cancer data.

Materials and methods

Data source

Cancer registry data

The Cixian Cancer Registry was established in 1974. Incidence and mortality rate data were published in Cancer Incidence in Five Continents (CI5VIII and CI5X).6, 7 The Shexian Cancer Registry was established in 2000 and the data were published in the Chinese Cancer Registry Annual Report (2008–2013). We extracted lung cancer incidence and mortality data from 1988 to 2011 in Cixian and from 2003 to 2011 in Shexian. The Hebei Provincial Cancer Registry Center is responsible for compiling cancer data, evaluations, and publications from local population‐based cancer registries. By 2010, there were eight cancer registries in Hebei Province comprising five counties (Cixian, Shexian, Qianxi, Wuan, and Zanhuang) and three cities (Baoding, Qinhuangdao, and Cangzhou). Cancer information is reported to cancer registries by local hospitals and community health centers, including the Basic Medical Insurances for Urban Residents and the New‐Rural Cooperative Medical System. The Vital Statistical Database is linked to the cancer incidence database to identify cases with death certificates only (DCO) and follow‐ups. By 1 June 2014, eight cancer registries had submitted 2011 data to the Hebei Provincial Cancer Registry Center. All cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition (ICD‐O‐3), and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10). Invasive cases of lung cancer (ICD10: C33‐C34) were extracted and analyzed from the overall cancer database.

Quality control

According to the “Guideline of Chinese Cancer Registration,” data was checked and evaluated using MS‐Excel, SAS version 8.0 (SAS Institute Inc., Cary, NC, USA), IARC Tools, and inclusion criteria from Cancer Incidence in Five Continents Volume X.7 , 8 Data were included in the analysis if they met the following criteria: the morphological verification (MV%) was higher than 66%, the percentage of cancer cases identified with DCO was less than 15%, and the mortality to incidence ratio (M/I) was between 0.6 and 0.8.

National retrospective survey of mortality

In the mid‐1970s, a nationwide retrospective survey of the causes of mortality was conducted in 29 provinces, including Hebei Province. This survey covered all 153 cities and counties in Hebei Province.9 A national retrospective sampling survey of cancer mortality from 1990 to 1992 was also carried out. This survey employed a stratified sampling method, and covered approximately 10% of the population in China. A total of 21 cities and counties from Hebei Province were enrolled as sampling areas.9, 10 In 2006, a national retrospective stratified sampling survey of all causes of death for the period 2004–2005 was performed in 31 provinces/municipalities/autonomous regions, including Hebei Province.11 A total of 18 cities and counties were selected as sampling areas.

Statistical analysis

Incidence and mortality rates were calculated by gender and age groups. The numbers of new cases and deaths were estimated using the five‐year age‐specific cancer incidence/mortality rates and the corresponding populations. World Segi's populations were used for age‐standardized rates. The cumulative risk of developing or dying from cancer before 75 years of age was calculated and presented as a percentage. SAS software was used to calculate incidence and mortality rates. Long‐term trends in age‐standardized rates of lung cancer in Cixian and Shexian were analyzed using a Joinpoint regression model.12 Joinpoint regression software version 4.0.4 (US National Cancer Institute, Bethesda, MD, USA) was used.

Results

Quality evaluation

The population of all eight cancer registries was 4 573 293. Lung cancer M/I in all cancer registry areas was 0.85 (0.85 men, 0.84 women); the MV% was 50.45% (53.14% men, 51.26% women); the DCO% was 7.27% (7.27% men, 7.26% women); and the M/I in urban areas was 0.85, which was higher than rural areas at 0.83. A total of 84.7%, 93.5%, and 95.8% of lung cancer cases were diagnosed at county hospital level or above in the surveys dated 1973–1975, 1990–1992, and 2004–2005, respectively. Fewer than 2.5% of lung cancer cases did not have clinical diagnosis materials, and over 94.6% of the causes of death were confirmed by clinical diagnoses or other advanced technologies in all three mortality surveys.

Overall incidence and mortality rates in Hebei Province in 2011

In 2011, the lung cancer crude incidence rate in the registry areas was 45.44/100 000 (56.93/100 000 for men, 33.62/100 000 for women), accounting for 18.44% of all cancers. The age‐adjusted rate standardized by the age structures of world populations (ASRW) was 39.01/100 000. For patients aged 0–74 years, the cumulative incidence rate was 4.46%. In urban areas, the incidence rate and ASRW were 61.17/100 000 (75.36/100 000 for men, 46.82/100 000 for women) and 51.82/100 000, respectively, while in rural areas, they were 31.60/100 000 (40.97/100 000 for men, 21.83/100 000 for women) and 27.24/100 000. Both the crude incidence rate and ASRW in urban areas were much higher than those in rural areas (Table 1).
Table 1

Lung cancer incidence and mortality in Hebei Province, 2011

AreaGenderIncidenceMortality
Crude rateRatioASRCASRWCRCrude rateRatioASRCASRWCR
0–740–74
(1/105)(%)(1/105)(1/105)(%)(1/105)(%)(1/105)(1/105)(%)
AllBoth45.4418.4438.5539.014.4638.4623.5334.5935.873.34
Male56.9321.5252.1053.585.9348.4324.6447.3549.264.58
Female33.6214.7626.9926.853.0728.2121.7823.6424.642.16
UrbanareasBoth61.1725.2150.7051.825.6852.2032.9446.6549.464.06
Male75.3630.3367.4570.197.2963.8434.6860.7864.365.47
Female46.8219.7836.5736.574.2240.4330.5034.2736.582.77
Rural areasBoth31.6012.6527.2327.243.3126.3815.7123.4823.702.66
Male40.9714.7137.2237.484.7035.0916.9334.0234.433.79
Female21.839.9417.9117.761.9517.3013.6414.2214.461.56

ASRC, age‐standardized rate (using China standard population,2000); ASRW, age‐standardized rate (using World standard population); CR, cumulative rate.

Lung cancer incidence and mortality in Hebei Province, 2011 ASRC, age‐standardized rate (using China standard population,2000); ASRW, age‐standardized rate (using World standard population); CR, cumulative rate. The lung cancer crude mortality rate was 38.46/100 000 (48.43/100 000 for men, 28.21/100 000 for women) and the ASRW was 35.87/100 000. The cumulative rate (0–74 years old) was 3.34%. The lung cancer crude mortality rate in urban areas was 52.20/100 000 (63.84/100 000 for men, 40.43/100 000 for women) and the ASRW was 49.46/100 000. Among patients aged 0–74 years, the cumulative incidence rate was 4.06%. In rural areas, the crude mortality rate was 26.38/100 000 (35.09/100 000 for men, 17.30/100 000 for women), the ASRW was 23.70/100 000, and the cumulative mortality (0–74 years) was 2.66%. Urban areas also had a higher mortality than rural areas (Table 1).

Mortality trend of lung cancer in Hebei Province from 1973 to 2011

The lung cancer mortality rate demonstrated a significantly increasing trend in Hebei Province from 1973 to 2011. In 1973–1975, the lung cancer crude mortality rate was 9.31/100 000 (11.82/100 000 for men, 6.70/100 000 for women). It increased to 35.22/100 000 (45.36 and 24.76 per 100 000 for men and women) in 2010–2011. During 1973–1975, lung cancer ASRW was 10.69 per 100 000, accounting for 9.45% of cancer deaths. During 1990–1992, it was 23.17 per 100 000, accounting for 16.76%. The lung cancer ASRW was 26.64 per 100 000 with aproportional mortality ratio (PMR) of 22.43% in 2004–2005. During 2010–2011, the lung cancer ASRW was 30.91 per 100 000 with a PMR of 22.46% of total cancer deaths. The mortality rate in 2010–2011 was 2.89 times that of the rate in 1973–1975. During the study period, the ASRW mortality rate increased for both men and women(Table 2, Fig 1). In addition, the median age of death of lung cancer was 62.8 years in 1973–1975, 64.9 years in 1990–1992, and increased from 68.2 years in 2004–2005 to 69.1 years in 2010–2011 (Fig 2).
Table 2

Lung cancer mortality in Hebei Province from 1973 to 2011

1973–19751990–19922004–20052010–2011
TotalMaleFemaleTotalMaleFemaleTotalMaleFemaleTotalMaleFemale
Cases1333686444692373924741265413227351397316620701096
CMR9.3111.826.7019.2624.8613.3729.8138.3920.7335.2245.3624.76
ASRC10.6913.807.5723.0431.0115.3626.7635.9417.8231.1043.5320.31
ASRW10.6913.847.5123.1731.2815.3126.6435.7617.7230.9143.3320.14
PMR9.4510.158.4016.7617.3615.7022.4323.2820.9322.4623.5820.62

ASRC, age‐standardized rate using China standard population (2000); ASRW, age‐standardized rate using World standard population; CMR, crude mortality rate; PMR, proportional mortality ratio.

Figure 1

Lung cancer mortality in Hebei Province from 1973 to 2011. ASRW, age‐standardized rate (using World standard population); CMR, crude mortality rate; PMR, proportional mortality ratio. () 1973–1975; () 1990–1992; () 2004–2005; () 2010–2011.

Figure 2

The median age of death of lung cancer in Hebei Province from 1973 to 2011. () 1973–1975; () 1990–1992; () 2004–2005; () 2010–2011.

Lung cancer mortality in Hebei Province from 1973 to 2011 ASRC, age‐standardized rate using China standard population (2000); ASRW, age‐standardized rate using World standard population; CMR, crude mortality rate; PMR, proportional mortality ratio. Lung cancer mortality in Hebei Province from 1973 to 2011. ASRW, age‐standardized rate (using World standard population); CMR, crude mortality rate; PMR, proportional mortality ratio. () 1973–1975; () 1990–1992; () 2004–2005; () 2010–2011. The median age of death of lung cancer in Hebei Province from 1973 to 2011. () 1973–1975; () 1990–1992; () 2004–2005; () 2010–2011.

Age‐specific incidence and mortality rates in Hebei Province in 2011

The age‐specific incidence rate was low up to the age of 40 years and dramatically increased after age 40, reaching a peak in the 80+ age group at 551.01/100 000. The incidence rate also reached a peak at the age group of 80+ years at 931.48/100 000 in urban areas, with 1601.52/100 000 for urban men. In rural areas, the peak was reached in the 75 year age group at 235.68/100 000. For rural men, the incidence rate reached a peak at 80+ years at 307.09/100 000. The age‐specific incidence rate was higher in urban than in rural areas except in the 15, 25, and 30 year age groups. The incidence rate in men was higher than in women, except for the 20 and 35 year age groups (Table 3, Fig 3).
Table 3

Age‐specific lung cancer incidence in Hebei Province in 2011

Age groupAll areasUrban areasRural areas
BothMaleFemaleBothMaleFemaleBothMaleFemale
0‐0.000.000.000.000.000.000.000.000.00
5‐0.000.000.000.000.000.000.000.000.00
10‐0.000.000.000.000.000.000.000.000.00
15‐0.340.000.700.000.000.000.530.001.12
20‐0.250.000.500.690.001.410.000.000.00
25‐2.042.741.350.790.810.783.715.232.15
30‐2.662.882.421.541.012.104.165.392.86
35‐5.925.885.957.295.469.124.306.382.18
40‐16.8917.5716.1823.4325.4421.3310.9210.3211.54
45‐31.7033.5429.7835.3434.2436.5028.1732.8423.42
50‐54.8564.7144.5758.6368.7248.1251.2360.8741.16
55‐109.43156.0264.01131.45181.2483.3588.01131.7145.02
60‐152.40197.92109.80192.15247.74141.39117.55155.2781.48
65‐247.27334.88164.59331.62430.89240.78170.42250.0193.14
70‐267.30369.52174.05353.02463.16258.31182.72282.6386.11
75‐387.87518.01276.46544.32735.34377.36235.68301.89180.13
80 +551.01975.99301.69931.481601.52469.76213.43307.09164.88
Figure 3

Lung cancer incidence in Hebei Province in 2011. () All areas; () urban areas; () rural areas.

Age‐specific lung cancer incidence in Hebei Province in 2011 Lung cancer incidence in Hebei Province in 2011. () All areas; () urban areas; () rural areas. The age‐specific mortality rate was low up to the age of 40 years and began to increase after age 40. For men, the mortality rate reached a peak at 70 years of 88.82 and 270.38 per 100 000 in 1973–1975 and 1990–1992, respectively, while the peak in 2004–2005 and 2010–2011 was reached at 80+ years of 458.69 and 958.25 per 100 000, respectively. For women, the peak lung cancer mortality rate was in the 80+ age group, except in 1973–1975, when the peak was reached at 70 years of age (Table 4).
Table 4

Age‐specific lung cancer mortality in Hebei Province from 1973 to 2011

Age group1973–19751990–19922004–20052010–2011
MaleFemaleMaleFemaleMaleFemaleMaleFemale
0‐0.020.040.000.000.000.001.390.00
5‐0.060.020.000.000.000.000.000.00
10‐0.030.020.000.000.000.000.350.00
15‐0.220.150.340.230.440.000.320.70
20‐0.600.340.610.431.120.200.730.50
25‐1.030.671.491.571.181.020.710.23
30‐2.131.362.721.782.031.792.380.94
35‐4.812.665.393.876.753.105.722.77
40‐8.665.3112.216.329.627.0216.157.49
45‐17.069.9825.5214.0224.5511.3026.2911.55
50‐28.4518.0243.8328.7850.8422.0842.1423.08
55‐47.1324.7978.7638.5598.7537.2682.8138.43
60‐69.6533.11152.3063.41126.8863.74157.8570.90
65‐83.9639.92219.5091.79221.90103.52210.8997.39
70‐88.8248.19270.38125.98309.62171.56346.99157.32
75‐78.2646.92245.58122.43395.22176.07536.79261.31
80 +54.6240.41244.79155.75458.69278.43958.25444.09
Age‐specific lung cancer mortality in Hebei Province from 1973 to 2011 The age‐specific mortality trend during 1973–1975 and 1990–1992 was similar, while the trend of 2004–2005 was similar to that of 2010–2011, except in women. There was an increasing trend in all age groups with an increase in age, and a significantly increasing trend in people aged above 65 years in 2010–2011, compared with 1973–1975 (Table 4, Fig 4).
Figure 4

Age‐specific lung cancer mortality in Hebei Province from 1973 to 2011. () 1973–1975; () 1990–1992; () 2004–2005; () 2010–2011.

Age‐specific lung cancer mortality in Hebei Province from 1973 to 2011. () 1973–1975; () 1990–1992; () 2004–2005; () 2010–2011.

Lung cancer incidence rate trends in Cixian (1988–2011) and Shexian (2000–2011)

The lung cancer incidence rate has increased in Cixian, Hebei Province, with an annual percentage change (APC) of 3.87 and 4.50 in men and women, respectively, from 1988–2011 (Table 5, Fig 5). In 1988, the Cixian ASRW male lung cancer incidence rate was 45.11/100 000. It increased 46.35% in 2011, to 66.02/100 000. The ASRW female incidence rate was 21.83/100 000 in 1988, increasing 25.65% to 27.43/100 000 in 2011.
Table 5

Lung cancer incidence in Cixian, 1988–2011

YearMaleFemale
PopulationCasesCIRASRPopulationCasesCIRASR
1988262 7267327.7945.11260 1734316.5321.83
1989272 6436222.7433.47264 5393412.8517.01
1990289 3917024.1937.52285 8403913.6418.85
1991294 9935920.0031.79285 4373512.2616.12
1992299 3064515.0324.07287 546144.876.43
1993299 4986521.7029.27296 0603511.8213.53
1994303 7617123.3730.74295 104299.836.43
1995302 7827625.1032.34294 8674113.906.43
1996302 5377725.4533.91298 5953110.3812.21
1997306 3837925.7835.70298 5964113.7315.89
1998312 5669731.0342.60298 6944214.0616.03
1999316 2628827.8336.47300 2005116.9919.14
2000316 8768225.8835.32308 2714414.2717.07
2001322 51311134.4246.00313 5005216.5918.43
2002325 04812337.8449.47312 1996219.8622.10
2003327 87710331.4138.25312 5047022.423.67
2004309 54915048.4664.16294 4717324.7928.05
2005308 96314446.6163.78299 14310234.1042.94
2006314 37215047.7163.61300 6126822.6224.92
2007317 67117454.7775.93306 4137825.4628.76
2008320 48916551.4868.69308 8738126.2229.62
2009322 62114946.1863.41311 7128828.2334.23
2010320 85717554.5459.53315 6357022.1819.53
2011322 29019359.8866.02317 0469931.2327.43
APC3.87* 4.50*

*Annual percentage change (APC), P < 0.05. ASR, age‐standardized rate; CIR, crude incidence rate.

Figure 5

Lung cancer incidence in Cixian (1988–2011) and Shexian (2000–2011). () Cixian Male; () Cixian Female; () Shexian Male; () Shexian Female.

Lung cancer incidence in Cixian, 1988–2011 *Annual percentage change (APC), P < 0.05. ASR, age‐standardized rate; CIR, crude incidence rate. Lung cancer incidence in Cixian (1988–2011) and Shexian (2000–2011). () Cixian Male; () Cixian Female; () Shexian Male; () Shexian Female. Shexian demonstrates a similar trend (Table 6, Fig 5). In men, the incidence rate increased from 15.29/100 000 to 33.06/100 000 during 2000 to 2011, while in women, the rate increased from 9.87/100 000 to 11.25/100 000. There was an APC of 5.44 for men, but no significant statistical change to the APC for women in Shexian.
Table 6

Lung cancer incidence in Shexian, 2000–2011

YearMaleFemale
PopulationCasesCIRASRPopulationCasesCIRASR
2000197 5902412.1515.29183 274168.739.87
2001198 6552814.0916.67183 903158.169.24
2002199 5264020.0523.87184 536179.2110.02
2003200 1774220.9825.17185 074168.659.13
2004200 7544120.4221.98185 580126.477.77
2005201 8587135.1737.89186 385179.1210.35
2006202 5036431.6038.01187 186179.088.11
2007203 4725426.5428.32187 9232814.9017.90
2008204 1756431.3532.11188 8932513.2411.62
2009205 1685526.8127.30189 7763015.8114.54
2010206 8955426.1025.51191 1502814.6513.33
2011192 5096935.8433.06179 9672513.8911.25
APC5.44*

*Annual percentage change (APC), P < 0.05. ASR, age‐standardized rate; CIR, crude incidence rate.

Lung cancer incidence in Shexian, 2000–2011 *Annual percentage change (APC), P < 0.05. ASR, age‐standardized rate; CIR, crude incidence rate.

Mortality rates of lung cancer in Cixian (1988–2011)and Shexian (2000–2011)

The lung cancer mortality rate increased in Cixian during the period 1988–2011, with an APC of 3.15 and 2.74 in men and women, respectively (Figure 6). In 1988, the ASRW lung cancer mortality rate in men in Cixian was 27.69/100 000. In 2011, it increased 82.09% to 50.42/100 000. In women, the ASRW mortality rate was 14.22/100 000 in 1988, and increased 29.54% in 2011 to 18.42/100 000. The lung cancer mortality rate also increased in Shexian from 2000 to 2011 (Fig 6). In men, the mortality rate increased 25.21%, from 17.69/100 000 to 22.15/100 000 in 2000–2011. In women, it increased 15.13%, from 9.19/100 000 to 10.58/100 000. However, there was no statistically significant APC in men or women.
Figure 6

Lung cancer mortality in Cixian (1988–2011) and Shexian (2000–2011). () Cixian Male; () Cixian Female; () Shexian Male; () Shexian Female.

Lung cancer mortality in Cixian (1988–2011) and Shexian (2000–2011). () Cixian Male; () Cixian Female; () Shexian Male; () Shexian Female.

Discussion

Globally, lung cancer is the largest contributor to new cancer diagnoses and deaths from cancer with a five‐year survival rate lower than 20%.13, 14 In 2012, there were 652 800 new cases and 597 200 deaths in China, accounting for 35.78% and 37.56% of the world. In 2011, 32 623 lung cancer patients resided in Hebei Province. The lung cancer incidence rate ranked second of all cancer deaths. Comparing our results with Globocan 2012 data, lung cancer incidence in Hebei Province in 2011 (ASRW = 39.01/100 000) was 1.08 times that of China (36.1/100 000) and 1.69 times world (23.1/100 000) rates. There were 27 612 lung cancer deaths in Hebei Province in 2011, with an ASRW of 35.87/100 000, higher than the average level of China (32.5/100 000) and the world (19.7/100 000). In 2011, lung cancer was the leading cause of cancer death in Hebei Province. In the first and second National Retrospective Death Cause Surveys, lung cancer was ranked fourth and third, respectively. However, by the third National Retrospective Death Cause Survey, lung cancer had replaced liver cancer as the leading cause of cancer death in China (accounting for 22.7% of the total cancer related deaths).15 The lung cancer mortality rate in Hebei Province also showed an ascending trend. The ASRW of lung cancer in Hebei Province were 10.69, 23.17, 26.64 and 30.91 per 100 000 in 1973–1975, 1990–1992, 2004–2005, and 2010–2011, respectively. The proportional mortality ratio of lung cancer in all tumors increased from 9.45% in 1973–1975, 16.76% in 1990–1992, and 22.43% in 2004–2005 to 22.46% in 2010–2011. Siegel et al. reported that the lung cancer death rate in men in the US decreased by 2.0% per year from 1994 to 2006.16 In women, although lung cancer death rates continued to increase by 0.3% per year from 1995 to 2005, more recent data show a decline of 0.9% per year from 2003 to 2006. These decreases in lung cancer death rates in the US result froman abundance of manpower, material, and financial resources. In 1995, the US established legislation for tobacco control, which had a substantial impact on the rapid decline in smoking rates. It is an immense task to decrease the lung cancer rate in Hebei Province. There is an obvious ascending trend in age‐specific mortality in Hebei Province during the last 40 years, especially in older adults. The median age at death of lung cancer was 68.5 and 70.4 years for men and women in Hebei Province in 2011, respectively. According to the German Federal Health Monitoring System, the mean age of lung cancer death in German men was 69.8 years and 70 years for women in 2007.17 Borsoi et al. reported a mean age of death from lung cancer in Austria of 68.7 years for men and of 69.3 years for women in 2007.18 The mean age of death from lung cancer in Hebei Province is roughly similar to that of Western countries. Cixian and Shexian counties in Hebei Province have population‐based cancer registries. Incidence data showed a significant increasing trend in the ASRW of lung cancer in Cixian during the period 1988–2011, with an APC of 3.87 and 4.50 in men and women, respectively. In Shexian, there was also a significant increase, with an APC of 5.44 in men during the period 2000–2011. The lung cancer mortality rate also increased in Cixian and Shexian. An efficient abatement of lung cancer risk factors is critical to reduce lung cancer incidence and mortality. China now consumes over a third of the world's cigarettes.19 The smoking prevalence associated with lung cancer has increased over the past four decades in Chinese men. In 1984, there were approximately 250 million smokers in China, 61% men and 7% women.20 Among Chinese men, tobacco‐attributed mortality has grown considerably since the 1990s, and during the 2010s, smoking will cause about 20% of all male deaths at ages 40–79 years, an increase from only 10% in the early 1990s.21 The prevalence has increased to about 367 million, with 52.9% men in 2012.22 In 2003 in Hebei Province, 16 640 residents were randomly selected by multiple stage sampling and surveyed. The study revealed a cigarette smoking rate of both sexes of 26.08%, with 48.09% men.23 The smoking prevalence in Hebei Province continues to increase. Scientific evidence clearly shows that tobacco exposure is significantly associated with the cause of lung cancer and among Chinese lung cancer patients, about 60–70% are ever‐smokers.14 In order to decrease the rate of lung cancer, tobacco control efforts must be greatly intensified in Hebei Province. China is also facing pressure over air pollution control.24 Southern Hebei is one of the most seriously polluted areas in China.25 In 2013, the Ministry of Environmental Protection (MEP) reported that the SO2 emissions in Hebei Province were 1.28 million tons, ranking third of all the provinces in China, while the NOXemissions were 1.65 million tons, ranking first. In addition, motor vehicle emissions of NOX in Hebei Province ranked first in 2013. Moreover, smoke (powder) dust emissions in Hebei Province ranked first with more than 1.2 million tons. Hebei Province was the largest contributor to industrial smoke (powder) dust emissions.26 Cohen et al. estimated that exposure to air pollution contributed to more than 60 000 lung cancer deaths per year worldwide.27 The American Cancer Society (ACS) reported that each 10 ug/m3 increment of fine particles (PM2.5) was associated with an 8–14% increase in lung cancer.28 Environmental protection in Hebei Province has been and will continue to be the focus of attention and a major task. Other risk factors for lung cancer in China include indoor air pollution from unventilated coal‐fueled stoves and cooking fumes, especially for Chinese women. In a prospective cohort study, never smoking women were analyzed from 1996 to 2009. Poor kitchen ventilation was associated with a 49% increase in lung cancer risk (hazard ratio [HR]: 1.49; 95% confidence interval [CI]: 1.15–1.95). Coal use with poor ventilation (HR: 1.69; 95% CI: 1.22–2.35) and 20 or more years of using coal with poor ventilation (HR: 2.03; 95% CI: 1.35–3.05) were also significantly associated.29 It is, thus, clear that indoor air pollution increases the risk of lung cancer and is an important public health issue in cities across China. Indoor air pollution in Hebei Province is an important public health problem. A study by Markowitz et al. demonstrated that asbestos exposure among non‐smokers (rate ratio = 3.6, 95% CI: 1.7–7.6) increased lung cancer mortality. The risk increased to 14.4 among smokers, as asbestos and smoking are supra‐additive.30 Some studies have shown that fruit consumption was associated with a decreased risk of lung cancer.31, 32 In common with any analysis of cancer registry data, our study has several limitations, although the quality of our data was high. Only eight cancer registries submitted complete data. Any long‐term trends cannot yet be integrally reflected. However, with the establishment of more registries and an improvement in quality, cancer registration data will provide more and more accurate information. Lung cancer incidence and mortality in Hebei Province has increased over the past 40 years. Studies of preventive and control strategies, such as smoking prevalence control, air pollution (including fog and haze) reduction, and cancer screening should be encouraged.

Disclosure

No authors report any conflict of interest.
  19 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

Review 2.  Lung cancer risk and consumption of vegetables and fruit: an evaluation based on a systematic review of epidemiological evidence from Japan.

Authors:  Kenji Wakai; Keitaro Matsuo; Chisato Nagata; Tetsuya Mizoue; Keitaro Tanaka; Ichiro Tsuji; Shizuka Sasazuki; Taichi Shimazu; Norie Sawada; Manami Inoue; Shoichiro Tsugane
Journal:  Jpn J Clin Oncol       Date:  2011-03-19       Impact factor: 3.019

3.  Trends in mortality and mean age at death from lung cancer in Austria (1975-2007).

Authors:  Livia Borsoi; Ursula Kunze; Michael Kunze; Ernest Groman; Michael Kundi
Journal:  Cancer Epidemiol       Date:  2010-07-29       Impact factor: 2.984

Review 4.  Lung cancer molecular epidemiology in China: recent trends.

Authors:  Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2014-10

5.  Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution.

Authors:  C Arden Pope; Richard T Burnett; Michael J Thun; Eugenia E Calle; Daniel Krewski; Kazuhiko Ito; George D Thurston
Journal:  JAMA       Date:  2002-03-06       Impact factor: 56.272

6.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

7.  Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort.

Authors:  Steven B Markowitz; Stephen M Levin; Albert Miller; Alfredo Morabia
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

8.  Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009.

Authors:  Keisha A Houston; S Jane Henley; Jun Li; Mary C White; Thomas B Richards
Journal:  Lung Cancer       Date:  2014-08-12       Impact factor: 5.705

9.  Home kitchen ventilation, cooking fuels, and lung cancer risk in a prospective cohort of never smoking women in Shanghai, China.

Authors:  Christopher Kim; Yu-Tang Gao; Yong-Bing Xiang; Francesco Barone-Adesi; Yawei Zhang; H Dean Hosgood; Shuangge Ma; Xiao-ou Shu; Bu-Tian Ji; Wong-Ho Chow; Wei Jie Seow; Bryan Bassig; Qiuyin Cai; Wei Zheng; Nathaniel Rothman; Qing Lan
Journal:  Int J Cancer       Date:  2014-06-28       Impact factor: 7.396

10.  Quantifying the sources of the severe haze over the Southern Hebei using the CMAQ model.

Authors:  Jing Yang; Pu Zhang; Chenchen Meng; Jie Su; Zhe Wei; Fenfen Zhang; Wei Wei; Xiujuan Zhao
Journal:  ScientificWorldJournal       Date:  2013-09-15
View more
  10 in total

1.  Estimated cancer incidence and mortality in Hebei province, 2012.

Authors:  Yutong He; Di Liang; Daojuan Li; Jingbo Zhai; Junqing Zhu; Jing Jin; Denggui Wen; Baoen Shan
Journal:  Chin J Cancer Res       Date:  2016-06       Impact factor: 5.087

2.  Cancer incidence and mortality in Hebei province, 2013.

Authors:  Yutong He; Di Liang; Daojuan Li; Jin Shi; Jing Jin; Jingbo Zhai; Denggui Wen; Baoen Shan
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

3.  Cancer survival in Cixian of China, 2003-2013: a population-based study.

Authors:  Dongfang Li; Daojuan Li; Guohui Song; Di Liang; Chao Chen; Yachen Zhang; Zhaoyu Gao; Yutong He
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

4.  Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study.

Authors:  Difei Yao; Hong Shen; Jianjin Huang; Ying Yuan; Haibin Dai
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

5.  Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease.

Authors:  Ning Li; Haisheng Hu; Ge Wu; Baoqing Sun
Journal:  J Int Med Res       Date:  2019-07-01       Impact factor: 1.671

6.  Trend analysis of lung cancer mortality and years of life lost (YLL) rate from 1999 to 2016 in Tianjin, China: Does the lung cancer burden in rural areas exceed that of urban areas?

Authors:  Wenlong Zheng; Hui Zhang; Chengfeng Shen; Shuang Zhang; Dezheng Wang; Wei Li; Guohong Jiang
Journal:  Thorac Cancer       Date:  2020-03-03       Impact factor: 3.500

7.  Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China.

Authors:  Jin Shi; Daojuan Li; Di Liang; Yutong He
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

8.  [Analysis on the Incidence and Economic Burden of Patients with Lung Cancer].

Authors:  Guo Tian; Li Bian; Xiaoli Xu; Shumei Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20

9.  The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer.

Authors:  Liqun Wang; Di Liang; Xiaoli Xu; Jing Jin; Shumei Li; Guo Tian; Zhaoyu Gao; Congmin Liu; Yutong He
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

10.  Fine particulate matter associated mortality burden of lung cancer in Hebei Province, China.

Authors:  Yutong He; Zhaoyu Gao; Tiantian Guo; Feng Qu; Di Liang; Daojuan Li; Jin Shi; Baoen Shan
Journal:  Thorac Cancer       Date:  2018-05-14       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.